Biotechnology
Home » Recombinant Vaccines Market

Recombinant Vaccines Market

Recombinant Vaccines Market By Disease (Infectious Diseases, Cancer) – Growth, Future Prospects, And Competitive Analysis, 2017 -2025
Report Book

Published Date: Nov 2017
Category:Biotechnology
Report ID:58819
Report Format: PDF
No of Pages: 120

Rating: Credence Reports

Market Insights

Vaccines play a significant role in the prevention and control of different forms of infectious diseases. In the previous years, killed or attenuated vaccines were used, gradually transitioning to a recombinant subunit approach in the last two decades. The use of recombinant technologies in the production of subunit vaccines simplifies, secures, and reduces costs. A recombinant vaccine is manufactured using recombinant DNA technology, and it offers the prime advantage that there is a complete absence of pathogens during the production and purification procedures, thus making the production procedure safer.

The research study titled “Recombinant Vaccines Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” covers in-depth information related to the recombinant vaccines market. The research study provides a comprehensive analysis based on different market segments, such as disease type and geography. Infectious diseases and cancer are covered in the disease type segment analysis. The infectious diseases segment is further classified as hepatitis B infection, herpes zoster infection, influenza infection, and other infectious diseases.

The global recombinant vaccines market is made up of North America (including the United States and Canada), Europe (including the United Kingdom and Germany), Asia Pacific (including Japan and China), Latin America (including Mexico and Brazil), and the Middle East and Africa (GCC). The market size and forecast for these regions, along with their cross-sectional segmentation, are provided in this report for the considered period. The regional markets are further studied in terms of major country-specific markets.

Quantitative data and qualitative information are included in this report for further understanding of the current market situation and possible future scenarios. Information such as market dynamics (drivers, opportunities, and challenges) gives a detailed idea of the current developments in the global recombinant vaccine market. The report also includes competitive profiling of prominent players, attractive investment propositions, and market positions of key leaders involved in the global recombinant vaccine market to assist with strategic decisions about the recombinant vaccine market.

Based on disease type, the global recombinant vaccine market is segmented as follows:

Infectious diseases

  • Hepatitis B infection
  • herpes zoster infection
  • Influenza Infection
  • Other Infectious Diseases
  • Cancer

According to the World Health Organization (WHO), the vaccine market is essentially dependent on the governments of industrialized and developing countries, the private sector, and various regulatory and advisory bodies. Recombinant DNA vaccines are third-generation vaccines produced by using recombinant DNA technology or genetic engineering to prevent different diseases. These vaccines are more advanced than conventional vaccines in preventing diseases such as hepatitis, herpes, papillomavirus infection, influenza, etc. The recombinant vaccines market will grow significantly during the forecast period as it involves a novel method to elicit humoral as well as cellular immune responses, reduced risk of pathogenicity, and an easier approach for large-scale production.

In 1986, the first hepatitis B recombinant vaccine was approved in the United States. Currently, hepatitis B infection is a major revenue-generating segment, as the hepatitis B vaccine is included in the World Health Organization’s list of essential medicines. Moreover, the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics (AAP), and the American College of Obstetricians and Gynecologists (ACOG) also strongly recommend hepatitis B vaccination. Currently, hepatitis B recombinant vaccine revenue is largely generated by Engerix-B, Recombivax-HB, Pediarix, Comvax, Twinrix, etc. GlaxoSmithKline and Merck are the key players in the hepatitis B vaccine market. Promising pipeline vaccines such as VPM1002 (BCG), EBOV-GP (Ebola), Shingrix (Herpes Zoster), GSK-2189242A (pneumococcal infections), ID-93 (tuberculosis), PROSTVAC-VF (prostate cancer), etc. are expected to further assist the market’s growth during the forecast period of 2017–2025.

The recombinant vaccines market is divided into three segments for the purposes of this study:

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Europe
  • Latin America
    • Brazil
    • Mexico
    • rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of the Middle East and Africa

Recombinant vaccines are a more advanced, efficient, and safe technique produced by using recombinant DNA technology or genetic engineering. According to the World Health Organization (WHO), demand for vaccines mainly depends on the governments of countries, the pooling of procurement agencies, the proliferation of private players, and the presence and involvement of various regulatory and regulatory bodies overseeing vaccine safety and quality. The WHO also estimated that high-income countries such as the United States, the United Kingdom, France, etc., contribute over 80% of vaccine revenue due to the faster adoption of newer vaccines and higher costs. According to research, North America held the largest market share in 2016 due to higher recombinant vaccine costs, increased healthcare awareness, the strong recommendation of immunization programs, faster implementation of newer vaccines, and widespread availability of FDA-approved recombinant vaccines for various indications. Favorable R&D activities and the strong presence of pipeline vaccines such as VPM1002, EBOV-GP, Shingrix, GSK-2189242A, ID-93, PROSTVAC-VF, etc., would further assist the recombinant vaccine market’s growth in North America. It is also estimated that Asia Pacific will show the fastest market growth during the forecast period due to increasing healthcare awareness and rising government initiatives in the immunization program. According to the WHO, middle- and low-income countries generate approximately 18% of the value of total global vaccine sales, constituting around 80% of the annual volume sold. The WHO estimated that vaccine demand from the private sector is relatively small, i.e., about 5–10% of the total vaccine sales in developing countries.

Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Recombinant Vaccines Market Snapshot
2.2 Global Recombinant Vaccines Market, by Disease (US$ Bn)
2.3 Global Recombinant Vaccines Market Share, by Geography, 2016 (Value %)

Chapter 3 Recombinant Vaccines Market Analysis
3.1 Global Recombinant Vaccines Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition, 2016
3.4 Competitive Landscape of Key Players in Recombinant Vaccines Market
3.5 Top 3 Countries

Chapter 4 Pipeline Analysis of Recombinant Vaccines
4.1 Overview
4.2 Projected Sales of Phase III Recombinant Vaccines Estimated Till 2025 (US$ Bn)
4.2 Tabular Representation of Phase II and I Recombinant Vaccines

Chapter 5 Global Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
5.1 Overview
5.2 Attractive Investment Proposition: Global Recombinant Vaccines Market, by Disease, 2016
5.3 Infectious Diseases
5.3.1 Hepatitis B Infection
5.3.2 Herpes Zoster Infection
5.3.3 Influenza Infection
5.3.4 Other Infectious Diseases
5.4 Cancer

Chapter 6 Global Recombinant Vaccines Market, by Geography, 2015-2025 (US$ Bn)
6.1 Preface
6.2 North America
6.2.1 North America Recombinant Vaccines Market, by Disease, 2015- 2025 (US$ Bn)
6.2.2 North America Recombinant Vaccines Market, by Country, 2015- 2025 (US$ Bn)
6.2.2.1 United States
6.2.2.2 Canada
6.3 Europe
6.3.1 Europe Recombinant Vaccines Market, by Disease, 2015- 2025 (US$ Bn)
6.3.2 Europe Recombinant Vaccines Market, by Country, 2015- 2025 (US$ Bn)
6.3.2.1 U.K.
6.3.2.2 Germany
6.3.2.3 Rest of Europe
6.4 Asia Pacific
6.4.1 Asia Pacific Recombinant Vaccines Market, by Disease, 2015- 2025 (US$ Bn)
6.4.2 Asia Pacific Recombinant Vaccines Market, by Country, 2015- 2025 (US$ Bn)
6.4.2.1 China
6.4.2.2 Japan
6.4.2.3 Rest of Asia Pacific
6.5 Latin America
6.5.1 Latin America Recombinant Vaccines Market, by Disease, 2015- 2025 (US$ Bn)
6.5.2 Latin America Recombinant Vaccines Market, by Country, 2015- 2025 (US$ Bn)
6.5.2.1 Brazil
6.5.2.2 Mexico
6.5.2.3 Rest of Latin America
6.6 Middle East and Africa
6.6.1 Middle East and Africa Recombinant Vaccines Market, by Disease, 2015- 2025 (US$ Bn)
6.6.2 Middle East and Africa Recombinant Vaccines Market, by Country, 2015- 2025 (US$)
6.6.2.1 GCC
6.6.2.3 Rest of Middle East and Africa

Chapter 7 Company Profiles
7.1 Bharat Biotech
7.2 GlaxoSmithKline Plc.
7.3 MedImmune, LLC
7.4 Merck & Co. Inc.
7.5 Novartis AG
7.6 Pfizer Inc.
7.7 Protein Science Corporation
7.8 Sanofi Aventis
7.9 Serum Institute of India

List of Figures

FIG. 1 Recombinant Vaccines Market: Research Methodology
FIG. 2 Global Recombinant Vaccines Market, by Disease, 2016 (US$ Bn)
FIG. 3 Global Recombinant Vaccines Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Recombinant Vaccines Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Recombinant Vaccines Market, by Disease, 2016
FIG. 6 Global Hepatitis B Infection Recombinant Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 7 Global Herpes Zoster Infection Recombinant Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 8 Global Influenza Infection Recombinant Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 9 Global Other Infectious Diseases Recombinant Vaccines Market, 2015 – 2025 (US$ Bn)
FIG. 10 Global Cancer Recombinant Vaccines Market, 2015 – 2025 (US$ Bn)

List of Tables

TABLE 1 Market Positioning of Key Players in Global Recombinant Vaccines Market
TABLE 2 Top 3 Countries in Global Recombinant Vaccines Market
TABLE 3 Global Recombinant Vaccines Market, by Disease, 2015 – 2025 (US$ Bn)
TABLE 4 Global Infectious Disease Recombinant Vaccines Market, by Type, 2015 – 2025 (US$ Bn)
TABLE 5 Global Recombinant Vaccines Market, by Geography, 2015 – 2025 (US$ Bn)
TABLE 6 North America Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
TABLE 7 North America Recombinant Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 8 Europe Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
TABLE 9 Europe Recombinant Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 10 Asia Pacific Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
TABLE 11 Asia Pacific Recombinant Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 12 Latin America Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
TABLE 13 Latin America Recombinant Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 14 Middle East and Africa Recombinant Vaccines Market, by Disease, 2015-2025 (US$ Bn)
TABLE 15 Middle East and Africa Recombinant Vaccines Market, by Country, 2015 – 2025 (US$ Bn)
TABLE 16 Bharat Biotech: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 GlaxoSmithKline Plc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 MedImmune, LLC: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Merck & Co. Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Protein Science Corporation: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Sanofi Aventis: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Serum Institute of India: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

Frequently Asked Questions

What is the size of Recombinant Vaccines Market?

The market for Recombinant Vaccines is expected to reach US$ XX Mn in 2025.

What is the Recombinant Vaccines Market CAGR?

The Recombinant Vaccines market is expected to see significant CAGR growth over the coming years,at 6.4%.

What is the Forecast period considered for Recombinant Vaccines Market?

The report is forecasted from 2017-2025.

What is the base year considered for Recombinant Vaccines Market?

The base year of this report is 2016.

Who are the major players in this Market?

Bharat Biotech,GlaxoSmithKline Plc., MedImmune, LLC, Merck & Co. Inc.Novartis AG are some of the major players in the global market.

Biotechnology

Mass Spectrometry Market

Published Date: Aug. 2023
Category: Biotechnology
Report ID: 58466
Report Format: PDF
No of Pages: 246

Biotechnology

Aptamers Market

Published Date: Aug 2023
Category: Biotechnology
Report ID: 59152
Report Format: PDF
No of Pages: 240

Biotechnology

Biologic Imaging Reagents Market

Published Date: August 2023
Category: Biotechnology
Report ID: 62085
Report Format: PDF
No of Pages: 215

Biotechnology

Agriculture Biotechnology Market

Published Date: Aug 2023
Category: Biotechnology
Report ID: 62073
Report Format: PDF
No of Pages: 228

Biotechnology

Monoclonal Antibody Custom Service Market

Published Date: August 2023
Category: Biotechnology
Report ID: 62059
Report Format: PDF
No of Pages: 243

Biotechnology

Capsule Endoscope and Workstation Market

Published Date: Aug 2023
Category: Biotechnology
Report ID: 62054
Report Format: PDF
No of Pages: 225

Biotechnology

Cell Separation Technologies Market

Published Date: Aug 2023
Category: Biotechnology
Report ID: 62053
Report Format: PDF
No of Pages: 247

Biotechnology

DNA Probe-Based Diagnostics Market

Published Date: Aug 2023
Category: Biotechnology
Report ID: 62051
Report Format: PDF
No of Pages: 228

Biotechnology

Terpenes Market

Published Date: August 2023
Category: Biotechnology
Report ID: 60946
Report Format: PDF
No of Pages: 166

Biotechnology

Cell Isolation And Separation Market

Published Date: July 2023
Category: Biotechnology
Report ID: 59149
Report Format: PDF
No of Pages: 224

Biotechnology

Biological Product Manufacturing Market

Published Date: July 2023
Category: Biotechnology
Report ID: 61994
Report Format: PDF
No of Pages: 232

Biotechnology

Mobile Water Treatment Systems Market

Published Date: July 2023
Category: Biotechnology
Report ID: 61323
Report Format: PDF
No of Pages: 232

Download Sample Report


Have a question?

User Profile

Don’t settle for less – trust Mitul to help you find the best solution.

Report delivery within 24 to 48 hours

– Other Info –

What people say?-

User Review

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –

Phone

+91 6232 49 3207


support

24/7 Research Support


sales@credenceresearch.com

– Research Methodology –

Going beyond the basics: advanced techniques in research methodology

– Trusted By –

Pepshi, LG, Nestle
Motorola, Honeywell, Johnson and johnson
LG Chem, SIEMENS, Pfizer
Unilever, Samsonite, QIAGEN
WhatsApp Now